全脑放疗对EGFR突变晚期NSCLC的疗效:TKI初治与TKI耐药比较
全体患者两组间无统计学显著差异,但Lung-molGPA 2.5-4亚组中TKI初治组颅内PFS和OS更优。
要点
- 全体患者WBRT后颅内PFS与OS在TKI初治和耐药组间无统计学显著差异。
- Lung-molGPA 0-2亚组两组颅内PFS和OS均无显著差异。
- Lung-molGPA 2.5-4亚组TKI初治组颅内PFS和OS优于耐药组。
核心结论
- 全体EGFR突变多发脑转移NSCLC患者中,WBRT前TKI初治与TKI耐药两组的颅内PFS和OS无统计学显著差异。
- Lung-molGPA 2.5-4亚组中TKI初治组的颅内PFS和OS优于TKI耐药组。
研究设计与样本
- 采用Kaplan-Meier法分析颅内PFS和OS。
主要发现
- 全体患者WBRT后中位颅内PFS为7.7 vs. 5.4个月(p=0.052),中位OS为11.2 vs. 9.2个月(p=0.106),均无统计学显著差异。
- Lung-molGPA 0-2亚组中位颅内PFS为6.2 vs. 5.2个月(p=0.123),中位OS为7.8 vs. 6.7个月(p=0.514),均无显著差异。
- Lung-molGPA 2.5-4亚组颅内PFS为12.8 vs. 10.1个月,OS为23.3 vs. 15.3个月。
关键数值与推荐
- 全体患者颅内PFS:7.7 vs. 5.4个月,p=0.052;OS:11.2 vs. 9.2个月,p=0.106。
- Lung-molGPA 0-2组颅内PFS:6.2 vs. 5.2个月,p=0.123;OS:7.8 vs. 6.7个月,p=0.514。
- Lung-molGPA 2.5-4组颅内PFS:12.8 vs. 10.1个月;OS:23.3 vs. 15.3个月。
临床怎么用
- 对于EGFR突变多发脑转移患者,WBRT前是否TKI耐药可作为分层参考,尤其Lung-molGPA 2.5-4者TKI初治可能获益更多。
- Lung-molGPA 0-2患者中TKI初治与耐药状态对WBRT后疗效影响不显著。
局限性
- 本研究为回顾性分析,可能存在选择偏倚。
- Lung-molGPA 2.5-4亚组未报告统计学检验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The development of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has dramatically improved the prognosis of patients with EGFR-mutant non-small-cell lung cancer (NSCLC). The purpose of this study is to investigate the clinical outcome with or without EGFR-TKI resistance before WBRT and the sequence between EGFT-TKIs and whole brain radiotherapy (WBRT) of EGFR-mutant NSCLC patients who developed multiple brain metastases (BMs). PATIENTS AND METHODS: Three hundred forty-four EGFR-mutant NSCLC patients with multiple BMs were reviewed. Enrolled patients were divided into TKI-naïve group and TKI-resistant group. The intracranial progression-free survival (PFS) and overall survival (OS) were analyzed via the Kaplan-Meier method. RESULTS: For patients with multiple BMs treated by WBRT, the median intracranial PFS and OS were longer in the TKI-naïve group than those in the TKI-resistant group, but there were no statistically significant between two groups (Intracranial PFS: 7.7 vs. 5.4 months, p = 0.052; OS: 11.2 vs. 9.2 months, p = 0.106). For patients with Lung-molGPA 0-2, no significant differences in median intracranial PFS (6.2 vs. 5.2 months, p = 0.123) and OS (7.8 vs. 6.7 months, p = 0.514) between TKI-naïve and TKI-resistant groups. For patients with Lung-molGPA 2.5-4, intracranial PFS: 12.8 vs. 10.1 months; OS: 23.3 vs. 15.3 months. CONCLUSIONS: Our study found that there were no difference in intracranial PFS and OS in all patients between the two groups of TKI-naïve and TKI-resistant. But for patients in subgroup of Lung-molGPA 2.5-4, there were a better intracranial PFS and OS in TKI-naïve group.
引用
- Zhao L, Cai X, Chen D, et al. Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant. Radiat Oncol. 2019. PMID: 31892337. doi:10.1186/s13014-019-1454-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。